PAS
BTAI icon

Point72 Asia (Singapore)’s BioXcel Therapeutics BTAI Stock Holding History

Point72 Asia (Singapore)’s Portfolio BTAI Stock Details BTAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-996
Closed -$5.96K – 897
2024
Q4 		$5.96K Buy
996
+47
+5% +$393 ﹤0.01% 775
2024
Q3 		$9.26K Sell
949
-944
-50% -$12.7K ﹤0.01% 869
2024
Q2 		$38.8K Buy
+1,893
New +$63.4K 0.01% 721

Other funds holding BTAI

M
Murchinson Toronto, Ontario, Canada $791M AUM 68.08% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BPA
Beacon Pointe Advisors Newport Beach, California $18.9B AUM 18.9% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Point72 Asia (Singapore)'s BTAI Position: Q1 2025 in Review

Point72 Asia (Singapore) sold out of BioXcel Therapeutics (BTAI) in Q1 2025, closing a stake of 996 shares — an estimated $5.96K sold.

Point72 Asia (Singapore) first reported a position in BTAI in Q2 2024 and held it in 3 quarters. The position peaked at $38.8K in Q2 2024. 31 funds tracked by Wall St. Rank hold BTAI as of Q1 2025.

  • Point72 Asia (Singapore) reported no remaining BioXcel Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Point72 Asia (Singapore) sold 996 BioXcel Therapeutics shares in Q1 2025, an estimated $5.96K.
  • Point72 Asia (Singapore) first reported a position in BioXcel Therapeutics in Q2 2024 and held it in 3 quarters.
  • Point72 Asia (Singapore)'s BioXcel Therapeutics position peaked at $38.8K in Q2 2024.
  • 31 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q1 2025.

Based on Point72 Asia (Singapore)'s 13F filing for Q1 2025, filed 15 May 2025.